Sasa M
Department of Pharmacology, Hiroshima University School of Medicine, Japan.
Nihon Shinkei Seishin Yakurigaku Zasshi. 1997 Apr;17(2):53-9.
Tandospirone (sedil) is a newly developed anxiolytic drug that has a much higher selective affinity for 5-HT1A than dopamine D2 receptors without the binding affinities with noradrenergic, dopaminergic, cholinergic and GABAergic receptors. This agent binds with 5-HT1A receptors located in both 5-HT neurons in the raphe nucleus and other postsynaptic neurons to induce hyperpolarization of the neurons by opening the K+ channels to eventually inhibit the target neuronal activities. With repeated administrations of tandospirone, a decrease in 5-HT2A receptor population was observed. Behavioral studies in experimental animals have demonstrated that tandospirone inhibits conflict in Vogel methods, aggressive behavior and muricide in manners similar to those of diazepam. In addition, tandospirone showed antistress effects in experimental models and antidepressive effects in forced swimming tests. Unlike diazepam, tandospirone does not produce sedative, sleep-inducing, anticonvulsant, nor muscle relaxant effects at doses effective for conflict tests. Drug dependance, one of the serious problems with bezodiazepine, is not observed with repeated treatment of tandospirone in rats and monkeys. Furthermore, tandospirone has been reported to show a significantly more superior or equipotent effect to diazepam in controlling autonomic disturbances, psychiatric cardiovascular and vegetative syndromes as well as neurosis in double blind clinical studies. These effects are probably due to the selective action of tandospirone on 5-HT1A receptors in the limbic system to eventuate anxiolytic and antidepressant effects. A decrease in 5-HT2A receptor population with repeated treatment of tandospirone may have contributed to the antidepressive effect. Furthermore, 5-HT1A receptors relatively, selectively distributed in the limbic system are not involved in sedation, sleep or muscle relaxation. Such unwanted effects of benzodiazepines are thus not observed with tandospirone treatment.
坦度螺酮(喜普妙)是一种新开发的抗焦虑药物,对5-羟色胺1A(5-HT1A)的选择性亲和力远高于多巴胺D2受体,且与去甲肾上腺素能、多巴胺能、胆碱能和γ-氨基丁酸能(GABAergic)受体均无结合亲和力。该药物与中缝核5-羟色胺(5-HT)神经元及其他突触后神经元中的5-HT1A受体结合,通过打开钾离子通道诱导神经元超极化,最终抑制目标神经元活动。重复给予坦度螺酮后,可观察到5-HT2A受体数量减少。对实验动物的行为学研究表明,坦度螺酮在Vogel法中抑制冲突、攻击行为和杀鼠行为的方式与地西泮相似。此外,坦度螺酮在实验模型中显示出抗应激作用,在强迫游泳试验中显示出抗抑郁作用。与地西泮不同,在对冲突试验有效的剂量下,坦度螺酮不会产生镇静、助眠、抗惊厥或肌肉松弛作用。在大鼠和猴子中重复给予坦度螺酮未观察到药物依赖性,而药物依赖性是苯二氮䓬类药物的严重问题之一。此外,在双盲临床研究中,据报道坦度螺酮在控制自主神经紊乱、精神性心血管和植物神经综合征以及神经症方面,对焦虑和抑郁的治疗效果明显优于或等同于地西泮。这些作用可能归因于坦度螺酮对边缘系统中5-HT1A受体的选择性作用,从而产生抗焦虑和抗抑郁作用。重复给予坦度螺酮导致5-HT2A受体数量减少可能有助于其抗抑郁作用。此外,相对选择性分布于边缘系统的5-HT1A受体不参与镇静、睡眠或肌肉松弛。因此,坦度螺酮治疗不会出现苯二氮䓬类药物的此类不良反应。